Activity of meropenem/vaborbactam and comparators against non-carbapenemase-producing carbapenem-resistant Enterobacterales isolates from Europe.
Journal
JAC-antimicrobial resistance
ISSN: 2632-1823
Titre abrégé: JAC Antimicrob Resist
Pays: England
ID NLM: 101765283
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
08
06
2022
accepted:
20
08
2022
entrez:
5
10
2022
pubmed:
6
10
2022
medline:
6
10
2022
Statut:
epublish
Résumé
Carbapenem-resistant Enterobacterales (CRE) isolates have disseminated worldwide. CREs usually produce a carbapenemase; however, some isolates are negative for known carbapenemases. In this study, we evaluated the activity of meropenem/vaborbactam and comparators against CREs without a carbapenemase (nonCP CREs) collected from European hospitals from 2016 to 2019. 23 Most nonCP CRE were Meropenem/vaborbactam had potent
Sections du résumé
Background
UNASSIGNED
Carbapenem-resistant Enterobacterales (CRE) isolates have disseminated worldwide. CREs usually produce a carbapenemase; however, some isolates are negative for known carbapenemases. In this study, we evaluated the activity of meropenem/vaborbactam and comparators against CREs without a carbapenemase (nonCP CREs) collected from European hospitals from 2016 to 2019.
Materials and methods
UNASSIGNED
23
Results
UNASSIGNED
Most nonCP CRE were
Conclusions
UNASSIGNED
Meropenem/vaborbactam had potent
Identifiants
pubmed: 36196439
doi: 10.1093/jacamr/dlac097
pii: dlac097
pmc: PMC9524562
doi:
Types de publication
Journal Article
Langues
eng
Pagination
dlac097Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
Références
Antimicrob Agents Chemother. 2020 Sep 21;64(10):
pubmed: 32747358
Antimicrob Agents Chemother. 2020 May 21;64(6):
pubmed: 32152086
BMC Infect Dis. 2018 May 3;18(1):205
pubmed: 29724185
Virulence. 2017 May 19;8(4):460-469
pubmed: 27593176
Infect Drug Resist. 2018 Aug 15;11:1183-1187
pubmed: 30147346
Curr Opin Crit Care. 2020 Oct;26(5):433-441
pubmed: 32739970
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5454-8
pubmed: 27381386
Lancet Infect Dis. 2017 Feb;17(2):153-163
pubmed: 27866944
Genes (Basel). 2020 Oct 13;11(10):
pubmed: 33066176
Clin Microbiol Rev. 2020 Nov 11;34(1):
pubmed: 33177185
Int J Antimicrob Agents. 2018 Dec;52(6):898-905
pubmed: 29621592
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S521-S528
pubmed: 31724045
Front Microbiol. 2016 Jun 13;7:895
pubmed: 27379038
Lancet. 2022 Feb 12;399(10325):629-655
pubmed: 35065702
Antimicrob Agents Chemother. 2020 Jan 27;64(2):
pubmed: 31712199
Int J Antimicrob Agents. 2020 Jul;56(1):106011
pubmed: 32417206
Clin Infect Dis. 2021 Apr 8;72(7):e169-e183
pubmed: 33106864
Antimicrob Agents Chemother. 2017 Oct 24;61(11):
pubmed: 28848018
Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S1-S4
pubmed: 30895209
Antimicrob Agents Chemother. 2019 Sep 23;63(10):
pubmed: 31383670
Antimicrob Agents Chemother. 2019 Jun 24;63(7):
pubmed: 31085510
Antimicrob Agents Chemother. 2017 Nov 22;61(12):
pubmed: 29038260
Clin Microbiol Rev. 2020 Feb 26;33(2):
pubmed: 32102899
Clin Infect Dis. 2017 Feb 1;64(3):257-264
pubmed: 28013264
J Antimicrob Chemother. 2021 Sep 15;76(10):2600-2605
pubmed: 34302173
Int J Antimicrob Agents. 2021 Nov;58(5):106439
pubmed: 34547421
J Antimicrob Chemother. 2020 Nov 1;75(11):3156-3162
pubmed: 32790858
Antimicrob Agents Chemother. 2021 Jan 20;65(2):
pubmed: 33139285